Diagnosis and management of microscopic colitis: Current perspectives

Clinical and Experimental Gastroenterology

Volumn 7, Issue 1, 2014, Pages 273-284

  Bohr, Johan ^a,c   Wickbom, Anna ^a,c   Hegedus, Agnes ^b   Nyhlin, Nils ^a,c   Hörnquist, Elisabeth Hultgren ^c   Tysk, Curt ^a,c  

^a Division of Gastroenterology Department of Medicine ^*  (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c ÖREBRO UNIVERSITY   (Sweden)

Author keywords

Budesonide; Chronic diarrhea; Collagenous colitis; Lymphocytic colitis; Microscopic colitis

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ADALIMUMAB; AZATHIOPRINE; BISMUTH SALICYLATE; BOSWELLIA SERRATA EXTRACT; BUDESONIDE; C REACTIVE PROTEIN; CALGRANULIN; COLESTYRAMINE; ERYTHROMYCIN; INFLIXIMAB; LACTOFERRIN; LOPERAMIDE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RANITIDINE; RUSCUS ACULEATUS EXTRACT; SALAZOSULFAPYRIDINE; SERTRALINE; TICLOPIDINE;

ANEMIA; AUTOIMMUNITY; BACTERIAL INFECTION; CANCER RISK; COLLAGENOUS COLITIS; COLON RESECTION; CONFOCAL LASER MICROSCOPY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FECES ANALYSIS; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HUMAN; ILEOSTOMY; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LOW DRUG DOSE; LYMPHOCYTIC COLITIS; MAINTENANCE THERAPY; MICROSCOPIC COLITIS; NONHUMAN; PREVALENCE; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REMISSION; REVIEW; SMOKING; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT;

EID: 84925515491     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S63905     Document Type: Review

References (136)

1. Nyhlin N, Bohr J, Eriksson S, Tysk C. Systematic review: microscopic colitis. Aliment Pharmacol Ther. 2006;23(11):1525-1534.
2. Pardi DS, Kelly C.P. Microscopic colitis. Gastroenterology. 2011;140(4): 1155-1165.
3. Münch A, Aust D, Bohr J, et al. Microscopic colitis: current status, present and future challenges: statements of the European Microscopic Colitis Group. J Crohns Colitis. 2012;6(9):932-945.
4. Lindström C.G. 'Collagenous colitis' with watery diarrhoea-a new entity? Pathol Eur. 1976;11(1):87-89.
5. Freeman H, Weinstein WM, Shnitka T, Wensel RH, Sartor V.E. Watery diarrhea syndrome associated with a lesion of the colonic basement membrane-lamina propria interface. Ann Royal Coll Phys Surg Can. 1976;9:A45.
6. Lazenby AJ, Yardley JH, Giardiello FM, Jessurun J, Bayless T.M. Lymphocytic ("microscopic") colitis: a comparative histopathologic study with particular reference to collagenous colitis. Hum Pathol. 1989;20(1):18-28.
7. Fekih M, Ben Hriz F, Sassi A, Matri S, Filali A, Boubaker J. [Microscopic colitis. A 20 cases series]. Tunis Med. 2006;84(7):403-406. French.
8. Garg PK, Singh J, Dhali GK, Mathur M, Sharma M.P. Microscopic colitis is a cause of large bowel diarrhea in Northern India. J Clin Gastroenterol. 1996;22(1):11-15.
9. Rubio-Tapia A, Martinez-Salgado J, García-Leiva J, Martinez-Benítez B, Uribe M. Microscopic colitides: a single center experience in Mexico. Int J Colorectal Dis. 2007;22(9):1031-1036.
10. Park YS, Baek DH, Kim WH, et al. Clinical characteristics of microscopic colitis in Korea: prospective multicenter study by KASID. Gut Liver. 2011;5(2):181-186.
11. Bohr J, Tysk C, Eriksson S, Järnerot G. Collagenous colitis in Örebro, Sweden, an epidemiological study 1984-1993. Gut. 1995;37(3): 394-397.
12. Olesen M, Eriksson S, Bohr J, Jarnerot G, Tysk C. Microscopic colitis: a common diarrhoeal disease. An epidemiological study in Örebro, Sweden, 1993-1998. Gut. 2004;53(3):346-350.
13. Wickbom A, Bohr J, Eriksson S, Udumyan R, Nyhlin N, Tysk C. Stable incidence of collagenous colitis and lymphocytic colitis in Örebro, Sweden, 1999-2008: a continuous epidemiological study. Inflamm Bowel Dis. 2013;19(11):2387-2393.
14. Pardi DS, Loftus EV Jr, Smyrk TC, et al. The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut. 2007;56(4):504-508.
15. Gentile NM, Khanna S, Loftus EV Jr, et al. The epidemiology of microscopic colitis in Olmsted County from 2002 to 2010: a population-based study. Clin Gastroenterol Hepatol. 2014;12(5):838-842.
16. Benchimol EI, Kirsch R, Viero S, Griffiths A.M. Collagenous colitis and eosinophilic gastritis in a 4-year old girl: a case report and review of the literature. Acta Paediatr. 2007;96(9):1365-1367.
17. Camarero C, Leon F, Colino E, et al. Collagenous colitis in children: clinicopathologic, microbiologic, and immunologic features. J Pediatr Gastroenterol Nutr. 2003;37(4):508-513.
18. Olesen M, Eriksson S, Bohr J, Jarnerot G, Tysk C. Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients. Gut. 2004;53(4):536-541.
19. Williams JJ, Kaplan GG, Makhija S, et al. Microscopic colitis-defining incidence rates and risk factors: a population-based study. Clin Gastroenterol Hepatol. 2008;6(1):35-40.
20. Stewart M, Andrews CN, Urbanski S, Beck PL, Storr M. The association of coeliac disease and microscopic colitis: a large population-based study. Aliment Pharmacol Ther. 2011;33(12):1340-1349.
21. Fernández-Bañares F, Salas A, Forné M, Esteve M, Espinós J, Viver J.M. Incidence of collagenous and lymphocytic colitis: a 5-year population-based study. Am J Gastroenterol. 1999;94(2):418-423.
22. Fernández-Bañares F, Salas A, Esteve M, et al. Evolution of the incidence of collagenous colitis and lymphocytic colitis in Terrassa, Spain: a population-based study. Inflamm Bowel Dis. 2011;17(4):1015-1020.
23. Agnarsdottir M, Gunnlaugsson O, Orvar KB, et al. Collagenous and lymphocytic colitis in Iceland. Dig Dis Sci. 2002;47(5):1122-1128.
24. Bjørnbak C, Engel PJ, Nielsen PL, Munck L.K. Microscopic colitis: clinical findings, topography and persistence of histopathological subgroups. Aliment Pharmacol Ther. 2011;34(10):1225-1234.
25. Vigren L, Olesen M, Benoni C, Sjöberg K. An epidemiological study of collagenous colitis in southern Sweden from 2001-2010. World J Gastroenterol. 2012;18(22):2821-2826.
26. Guagnozzi D, Lucendo AJ, Angueira-Lapeña T, González-Castillo S, Tenias Burillo J.M. Prevalence and incidence of microscopic colitis in patients with diarrhoea of unknown aetiology in a region in central Spain. Dig Liver Dis. 2012;44(5):384-388.
27. Thörn M, Sjöberg D, Ekbom A, et al. Microscopic colitis in Uppsala health region, a population-based prospective study 2005-2009. Scand J Gastroenterol. 2013;48(7):825-830.
28. Tysk C, Wickbom A, Nyhlin N, Eriksson S, Bohr J. Recent advances in diagnosis and treatment of microscopic colitis. Ann Gastroenterol. 2011;24(4):253-262.
29. Bohr J, Tysk C, Eriksson S, Abrahamsson H, Järnerot G. Collagenous colitis: a retrospective study of clinical presentation and treatment in 163 patients. Gut. 1996;39(96):846-851.
30. Bohr J, Larsson LG, Eriksson S, Järnerot G, Tysk C. Colonic perforation in collagenous colitis: an unusual complication. Eur J Gastroenterol Hepatol. 2005;17(1):121-124.
31. Allende DS, Taylor SL, Bronner M.P. Colonic perforation as a complication of collagenous colitis in a series of 12 patients. Am J Gastroenterol. 2008;103(10):2598-2604.
32. Abboud R, Pardi DS, Tremaine WJ, Kammer PP, Sandborn WJ, Loftus EV Jr. Symptomatic overlap between microscopic colitis and irritable bowel syndrome: a prospective study. Inflamm Bowel Dis. 2013;19(3):550-553.
33. Limsui D, Pardi DS, Camilleri M, et al. Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis. 2007;13(2):175-181.
34. Nyhlin N, Wickbom A, Montgomery SM, Tysk C, Bohr J. Long-term symptom burden and health-related quality of life in patients with collagenous and lymphocytic colitis; a case-control study. Aliment Pharmacol Ther. 2014;39(9):963-972.
35. Halpin SJ, Ford A.C. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2012;107(10):1474-1482.
36. Fernandez-Bañares F, Esteve M, Salas A, et al. Bile acid malabsorption in microscopic colitis and in previously unexplained functional chronic diarrhea. Dig Dis Sci. 2001;46(10):2231-2238.
37. Ung KA, Gillberg R, Kilander A, Abrahamsson H. Role of bile acids and bile acid binding agents in patients with collagenous colitis. Gut. 2000;46(2):170-175.
38. Ung KA, Kilander A, Willen R, Abrahamsson H. Role of bile acids in lymphocytic colitis. Hepatogastroenterology. 2002;49(44):432-437.
39. Wildt S, Nordgaard-Lassen I, Bendtsen F, Rumessen J.J. Metabolic and inflammatory faecal markers in collagenous colitis. Eur J Gastroenterol Hepatol. 2007;19(7):567-574.
40. Wagner M, Lampinen M, Sangfelt P, Agnarsdottir M, Carlson M. Budesonide treatment of patients with collagenous colitis restores normal eosinophil and T-cell activity in the colon. Inflamm Bowel Dis. 2010;16(7):1118-1126.
41. Wagner M, Peterson CG, Stolt I, et al. Fecal eosinophil cationic protein as a marker of active disease and treatment outcome in collagenous colitis: a pilot study. Scand J Gastroenterol. 2011;46(7-8):849-854.
42. Wagner M, Stridsberg M, Peterson CG, Sangfelt P, Lampinen M, Carlson M. Increased fecal levels of chromogranin A, chromogranin B, and secretoneurin in collagenous colitis. Inflammation. 2013;36(4): 855-861.
43. Cruz-Correa M, Milligan F, Giardiello FM, et al. Collagenous colitis with mucosal tears on endoscopic insufflation: a unique presentation. Gut. 2002;51(4):600.
44. Sherman A, Ackert JJ, Rajapaksa R, West AB, Oweity T. Fractured colon: an endoscopically distinctive lesion associated with colonic perforation following colonoscopy in patients with collagenous colitis. J Clin Gastroenterol. 2004;38(4):341-345.
45. Wickbom A, Lindqvist M, Bohr J, et al. Colonic mucosal tears in collagenous colitis. Scand J Gastroenterol. 2006;41(6):726-729.
46. Kiesslich R, Hoffman A, Goetz M, et al. In vivo diagnosis of collagenous colitis by confocal endomicroscopy. Gut. 2006;55(4):591-592.
47. Meining A, Schwendy S, Becker V, Schmid RM, Prinz C. In vivo histopathology of lymphocytic colitis. Gastrointest Endosc. 2007;66(2):398-399.
48. Zambelli A, Villanacci V, Buscarini E, Bassotti G, Albarello L. Collagenous colitis: a case series with confocal laser microscopy and histology correlation. Endoscopy. 2008;40(7):606-608.
49. Magro F, Langner C, Driessen A, et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis. 2013;7(10):827-851.
50. Münch A, Langner C. Microscopic colitis: clinical and pathologic perspectives. Clin Gastroenterol Hepatol. Epub January 7, 2014.
51. Aust D, Münch A, Olesen M, et al. Topographical distribution of collagenous colitis-a pooled histological analysis of 2 European prospective multicenter trials. Gastroenterology. 2013;144 Suppl 1:S421.
52. Warren BF, Edwards CM, Travis S.P. 'Microscopic colitis': classification and terminology. Histopathology. 2002;40(4):374-376.
53. Goldstein NS, Bhanot P. Paucicellular and asymptomatic lymphocytic colitis: expanding the clinicopathologic spectrum of lymphocytic colitis. Am J Clin Pathol. 2004;122(3):405-411.
54. Fernández-Bañares F, Casalots J, Salas A, et al. Paucicellular lymphocytic colitis: is it a minor form of lymphocytic colitis? A clinical pathological and immunological study. Am J Gastroenterol. 2009;104(5):1189-1198.
55. Libbrecht L, Croes R, Ectors N, Staels F, Geboes K. Microscopic colitis with giant cells. Histopathology. 2002;40(4):335-338.
56. Sandmeier D, Bouzourene H. Microscopic colitis with giant cells: a rare new histopathologic subtype? Int J Surg Pathol. 2004;12(1):45-48.
57. Yuan S, Reyes V, Bronner M.P. Pseudomembranous collagenous colitis. Am J Surg Pathol. 2003;27(10):1375-1379.
58. Rubio CA, Lindholm J. Cryptal lymphocytic coloproctitis: a new phenotype of lymphocytic colitis? J Clin Pathol. 2002;55(2): 138-140.
59. Saurine TJ, Brewer JM, Eckstein R.P. Microscopic colitis with granulomatous inflammation. Histopathology. 2004;45(1):82-86.
60. Chang F, Deere H, Vu C. Atypical forms of microscopic colitis: morphological features and review of the literature. Adv Anat Pathol. 2005;12(4):203-211.
61. Abdo AA, Zetler PJ, Halparin L.S. Familial microscopic colitis. Can J Gastroenterol. 2001;15(5):341-343.
62. Freeman H.J. Familial occurrence of lymphocytic colitis. Can J Gastroenterol. 2001;15(11):757-760.
63. Järnerot G, Hertervig E, Grännö C, et al. Familial occurrence of microscopic colitis: a report on five families. Scand J Gastroenterol. 2001;36(9):959-962.
64. van Tilburg AJ, Lam HG, Seldenrijk CA, et al. Familial occurrence of collagenous colitis. A report of two families. J Clin Gastroenterol. 1990;12(3):279-285.
65. Fine KD, Do K, Schulte K, et al. High prevalence of celiac sprue-like HLA-DQ genes and enteropathy in patients with the microscopic colitis syndrome. Am J Gastroenterol. 2000;95(8):1974-1982.
66. Koskela RM, Karttunen TJ, Niemelä SE, Lehtola JK, Ilonen J, Karttunen R.A. Human leucocyte antigen and TNFα polymorphism association in microscopic colitis. Eur J Gastroenterol Hepatol. 2008;20(4):276-282.
67. Madisch A, Hellmig S, Schreiber S, Bethke B, Stolte M, Miehlke S. Allelic variation of the matrix metalloproteinase-9 gene is associated with collagenous colitis. Inflamm Bowel Dis. 2011;17(11): 2295-2298.
68. Madisch A, Hellmig S, Schreiber S, Bethke B, Stolte M, Miehlke S. NOD2/CARD15 gene polymorphisms are not associated with collagenous colitis. Int J Colorectal Dis. 2007;22(4):425-428.
69. Abraham C, Cho J.H. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066-2078.
70. Xavier RJ, Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427-434.
71. Armes J, Gee DC, Macrae FA, Schroeder W, Bhathal P.S. Collagenous colitis: jejunal and colorectal pathology. J Clin Pathol. 1992;45(9): 784-787.
72. Mosnier JF, Larvol L, Barge J, et al. Lymphocytic and collagenous colitis: an immunohistochemical study. Am J Gastroenterol. 1996;91(4): 709-713.
73. Göranzon C, Kumawat AK, Hultgren-Hörnqvist E, et al. Immunohistochemical characterization of lymphocytes in micro-scopic colitis. J Crohns Colitis. 2013;7(10):e434-e442.
74. Kumawat AK, Strid H, Elgbratt K, Tysk C, Bohr J, Hultgren Hörnquist E. Microscopic colitis patients have increased proportions of Ki67(+) proliferating and CD45RO(+) active/memory CD8(+) and CD4(+)8(+) mucosal T cells. J Crohns Colitis. 2013;7(9):694-705.
75. Elgbratt K, Kurlberg G, Hahn-Zohric M, Hörnquist E.H. Rapid migration of thymic emigrants to the colonic mucosa in ulcerative colitis patients. Clin Exp Immunol. 2010;162(2):325-336.
76. Kumawat AK, Elgbratt K, Tysk C, Bohr J, Hörnquist E.H. Reduced T cell receptor excision circle levels in the colonic mucosa of microscopic colitis patients indicate local proliferation rather than homing of peripheral lymphocytes to the inflamed mucosa. Biomed Res Int. 2013;2013:408638.
77. Järnerot G, Tysk C, Bohr J, Eriksson S. Collagenous colitis and fecal stream diversion. Gastroenterology. 1995;109(2):449-455.
78. Kumawat AK, Strid H, Tysk C, Bohr J, Hörnquist E.H. Microscopic colitis patients demonstrate a mixed Th17/Tc17 and Th1/Tc1 mucosal cytokine profile. Mol Immunol. 2013;55(3-4):355-364.
79. Tagkalidis PP, Gibson PR, Bhathal P.S. Microscopic colitis demonstrates a T helper cell type 1 mucosal cytokine profile. J Clin Pathol. 2007;60(4):382-387.
80. Günaltay S, Nyhlin N, Kumawat AK, et al. Differential expression of IL-1/TLR signaling regulators in microscopic and ulcerative colitis. World J Gastroenterol. In press 2014.
81. Taha Y, Carlson M, Thorn M, Loof L, Raab Y. Evidence of local eosinophil activation and altered mucosal permeability in collagenous colitis. Dig Dis Sci. 2001;46(4):888-897.
82. Taha Y, Raab Y, Larsson A, et al. Mucosal secretion and expression of basic fibroblast growth factor in patients with collagenous colitis. Am J Gastroenterol. 2003;98(9):2011-2017.
83. Taha Y, Raab Y, Larsson A, et al. Vascular endothelial growth factor (VEGF)-a possible mediator of inflammation and mucosal permeability in patients with collagenous colitis. Dig Dis Sci. 2004;49(1): 109-115.
84. Griga T, Tromm A, Schmiegel W, Pfisterer O, Müller KM, Brasch F. Collagenous colitis: implications for the role of vascular endothelial growth factor in repair mechanisms. Eur J Gastroenterol Hepatol. 2004;16(4):397-402.
85. Salas A, Fernández-Bañares F, Casalots J, et al. Subepithelial myofibroblasts and tenascin expression in microscopic colitis. Histopathology. 2003;43(1):48-54.
86. Medina C, Radomski M.W. Role of matrix metalloproteinases in intestinal inflammation. J Pharmacol Exp Ther. 2006;318(3):933-938.
87. Günther U, Schuppan D, Bauer M, et al. Fibrogenesis and fibrolysis in collagenous colitis. Patterns of procollagen types I and IV, matrix-metalloproteinase-1 and-13, and TIMP-1 gene expression. Am J Pathol. 1999;155(2):493-503.
88. Lundberg JO, Herulf M, Olesen M, et al. Increased nitric oxide production in collagenous and lymphocytic colitis. Eur J Clin Invest. 1997;27(10):869-871.
89. Olesen M, Middelveld R, Bohr J, et al. Luminal nitric oxide and epithelial expression of inducible and endothelial nitric oxide synthase in collagenous and lymphocytic colitis. Scand J Gastroenterol. 2003;38(1): 66-72.
90. Perner A, Andresen L, Normark M, et al. Expression of nitric oxide synthases and effects of L-arginine and L-NMMA on nitric oxide production and fluid transport in collagenous colitis. Gut. 2001;49(3): 387-394.
91. Perner A, Nordgaard I, Matzen P, Rask-Madsen J. Colonic production of nitric oxide gas in ulcerative colitis, collagenous colitis and uninflamed bowel. Scand J Gastroenterol. 2002;37(2):183-188.
92. Bonderup OK, Hansen JB, Madsen P, Vestergaard V, Fallingborg J, Teglbjaerg P.S. Budesonide treatment and expression of inducible nitric oxide synthase mRNA in colonic mucosa in collagenous colitis. Eur J Gastroenterol Hepatol. 2006;18(10):1095-1099.
93. Münch A, Söderholm JD, Wallon C, Öst A, Olaison G, Ström M. Dynamics of mucosal permeability and inflammation in collagenous colitis before, during, and after loop ileostomy. Gut. 2005;54(8): 1126-1128.
94. Münch A, Söderholm JD, Öst A, Ström M. Increased transmucosal uptake of E. coli K12 in collagenous colitis persists after budesonide treatment. Am J Gastroenterol. 2009;104(3):679-685.
95. Bohr J, Nordfelth R, Järnerot G, Tysk C. Yersinia species in collagenous colitis: a serologic study. Scand J Gastroenterol. 2002;37(6): 711-714.
96. Erim T, Alazmi WM, O'Loughlin CJ, Barkin J.S. Collagenous colitis associated with Clostridium difficile: a cause effect? Dig Dis Sci. 2003;48(7):1374-1375.
97. Mäkinen M, Niemelä S, Lehtola J, Karttunen T.J. Collagenous colitis and Yersinia enterocolitica infection. Dig Dis Sci. 1998;43(6): 1341-1346.
98. Perk G, Ackerman Z, Cohen P, Eliakim R. Lymphocytic colitis: a clue to an infectious trigger. Scand J Gastroenterol. 1999;34(1):110-112.
99. LaSala PR, Chodosh AB, Vecchio JA, Schned LM, Blaszyk H. Seasonal pattern of onset in lymphocytic colitis. J Clin Gastroenterol. 2005;39(10):891-893.
100. Vigren L, Tysk C, Ström M, et al. Celiac disease and other autoimmune diseases in patients with collagenous colitis. Scand J Gastroenterol. 2013;48(8):944-950.
101. Wang Y, Liu XP, Zhao ZB, Chen JH, Yu C.G. Expression of CD4+ forkhead box P3 (FOXP3)+ regulatory T cells in inflammatory bowel disease. J Dig Dis. 2011;12(4):286-294.
102. Götlind YY, Raghavan S, Bland PW, Hörnquist E.H. CD4+FoxP3+ regulatory T cells from Gαi2-/-mice are functionally active in vitro, but do not prevent colitis. PLoS One. 2011;6(9):e25073.
103. Fernández-Bañares F, de Sousa MR, Salas A, et al. Epidemiological risk factors in microscopic colitis: a prospective case-control study. Inflamm Bowel Dis. 2013;19(2):411-417.
104. Vigren L, Sjöberg K, Benoni C, et al. Is smoking a risk factor for collagenous colitis? Scand J Gastroenterol. 2011;46(11): 1334-1339.
105. Yen EF, Pokhrel B, Du H, et al. Current and past cigarette smoking significantly increase risk for microscopic colitis. Inflamm Bowel Dis. 2012;18(10):1835-1841.
106. Fernández-Bañares F, de Sousa MR, Salas A, et al. Impact of current smoking on the clinical course of microscopic colitis. Inflamm Bowel Dis. 2013;19(7):1470-1476.
107. Beaugerie L, Pardi D.S. Review article: drug-induced microscopic colitis-proposal for a scoring system and review of the literature. Aliment Pharmacol Ther. 2005;22(4):277-284.
108. Miehlke S, Madisch A, Kupcinskas L, et al. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis. Gastroenterology. 2014;146(5):1222-1230.
109. Chande N, McDonald JW, Macdonald J.K. Interventions for treating lymphocytic colitis. Cochrane Database Syst Rev. 2008;(2): CD006096.
110. Chande N, McDonald JW, Macdonald J.K. Interventions for treating collagenous colitis. Cochrane Database Syst Rev. 2008;(2):CD003575.
111. Baert F, Schmit A, D'Haens G, et al. Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up. Gastroenterology. 2002;122(1):20-25.
112. Bonderup OK, Hansen JB, Birket-Smith L, Vestergaard V, Teglbjaerg PS, Fallingborg J. Budesonide treatment of collagenous colitis: a randomised, double blind, placebo controlled trial with morphometric analysis. Gut. 2003;52(2):248-251.
113. Miehlke S, Heymer P, Bethke B, et al. Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology. 2002;123(4):978-984.
114. Miehlke S, Madisch A, Karimi D, et al. Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study. Gastroenterology. 2009;136(7):2092-2100.
115. Bonderup OK, Hansen JB, Teglbjaerg PS, Christensen LA, Fallingborg J.F. Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial. Gut. 2009;58(1):68-72.
116. Miehlke S, Madisch A, Bethke B, et al. Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2008;135(5):1510-1516.
117. Miehlke S, Hansen JB, Madisch A, et al. Risk factors for symptom relapse in collagenous colitis after withdrawal of short-term budesonide therapy. Inflamm Bowel Dis. 2013;19(13):2763-2767.
118. Münch A, Bohr J, Miehlke S, et al. Low-dose budesonide is an effective maintenance therapy in collagenous colitis: results from the randomised, placebo-controlled BUC-63/COC-trial. United European Gastroenterol J. 2013;1(1S):A35.
119. Munck LK, Kjeldsen J, Philipsen E, Fischer Hansen B. Incomplete remission with short-term prednisolone treatment in collagenous colitis: a randomized study. Scand J Gastroenterol. 2003;38(6):606-610.
120. Gentile NM, Abdalla AA, Khanna S, et al. Outcomes of patients with microscopic colitis treated with corticosteroids: a population-based study. Am J Gastroenterol. 2013;108(2):256-259.
121. Calabrese C, Fabbri A, Areni A, Zahlane D, Scialpi C, Di Febo G. Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial. J Gastroenterol Hepatol. 2007;22(6):809-814.
122. Wildt S, Munck LK, Vinter-Jensen L, et al. Probiotic treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial with Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis. Inflamm Bowel Dis. 2006;12(5):395-401.
123. Madisch A, Miehlke S, Eichele O, et al. Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial. Int J Colorectal Dis. 2007;22(12):1445-1451.
124. Pardi DS, Loftus EV Jr, Tremaine WJ, Sandborn W.J. Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurine. Gastroenterology. 2001;120(6):1483-1484.
125. Münch A, Fernández-Bañares F, Munck L.K. Azathioprine and mercaptopurine in the management of patients with chronic, active microscopic colitis. Aliment Pharmacol Ther. 2013;37(8):795-798.
126. Riddell J, Hillman L, Chiragakis L, Clarke A. Collagenous colitis: oral low-dose methotrexate for patients with difficult symptoms: long-term outcomes. J Gastroenterol Hepatol. 2007;22(10):1589-1593.
127. Münch A, Bohr J, Vigren L, Tysk C, Ström M. Lack of effect of methotrexate in budesonide-refractory collagenous colitis. Clin Exp Gastroenterol. 2013;6:149-152.
128. Aram G, Bayless TM, Chen ZM, Montgomery EA, Donowitz M, Giardiello F.M. Refractory lymphocytic enterocolitis and tumor necrosis factor antagonist therapy. Clin Gastroenterol Hepatol. 2010;8(4):391-394.
129. Esteve M, Mahadevan U, Sainz E, Rodriguez E, Salas A, Fernández-Bañares F. Efficacy of anti-TNF therapies in refractory severe microscopic colitis. J Crohns Colitis. 2011;5(6):612-618.
130. Münch A, Ignatova S, Ström M. Adalimumab in budesonide and methotrexate refractory collagenous colitis. Scand J Gastroenterol. 2012;47(1):59-63.
131. Pola S, Fahmy M, Evans E, Tipps A, Sandborn W.J. Successful use of infliximab in the treatment of corticosteroid dependent collagenous colitis. Am J Gastroenterol. 2013;108(5):857-858.
132. Fine KD, Ogunji F, Lee E, Lafon G, Tanzi M. Randomized, double blind, placebo-controlled trial of bismuth subsalicylate for microscopic colitis. Gastroenterology. 1999;116(4):A880.
133. Varghese L, Galandiuk S, Tremaine WJ, Burgart L.J. Lymphocytic colitis treated with proctocolectomy and ileal J-pouch-anal anastomosis: report of a case. Dis Colon Rectum. 2002;45(1):123-126.
134. Hjortswang H, Tysk C, Bohr J, et al. Health-related quality of life is impaired in active collagenous colitis. Dig Liver Dis. 2011;43(2): 102-109.
135. Hjortswang H, Tysk C, Bohr J, et al. Defining clinical criteria for clinical remission and disease activity in collagenous colitis. Inflamm Bowel Dis. 2009;15(12):1875-1881.
136. Madisch A, Heymer P, Voss C, et al. Oral budesonide therapy improves quality of life in patients with collagenous colitis. Int J Colorectal Dis. 2005;20(4):312-316.